icon-folder.gif   Conference Reports for NATAP  
  EASL 48th Annual Meeting
April 24th - 28th 2013
The Netherlands, Amsterdam
Back grey_arrow_rt.gif
All Oral Therapy With Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment-Experienced Genotype 2/3 HCV-Infected Patients: Results of the Phase 3 FUSION Trial
  Reported by Jules Levin
April 25, International Liver Congress 2013, Amsterdam
David Nelson1, Jordan Feld2, Kris V. Kowdley3, M. Tarek Al-Assi4, Ming Lin5, Hongmei Mo5, John McNally5, Diana M. Brainard5, William T. Symonds5, John G. McHutchison5, Keyur Patel6, Stuart Gordon7
1University of Florida, Gainesville, FL, USA; 2University of Toronto, Ontario, Canada; 3Digestive Disease Institute, Virginia Mason Medical Center, Seattle, WA, USA;
4Texas Digestive Disease Consultants, Arlington, TX, USA; 5Gilead Sciences, Inc., Foster City, CA, USA; 6Duke University, Durham, NC, USA; 7Henry Ford Health Systems, Detroit, MI, USA
ELECTRON: 100% SVR Rate for Once-Daily Sofosbuvir Plus Ledipasvir Plus Ribavirin Given for 12 Weeks in Treatment-Naïve and Previously Treated Patients With HCV GT 1........http://www.natap.org/2013/CROI/croi_07.htm
NEJM - Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options - (04/24/13)
The Lancet Infectious Diseases- Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial - (04/24/13)